Prolonged incubation period of AIDS in intravenous drug abusers: epidemiological evidence in prison inmates. NLM AIDSLINE Important note: Information in this article was accurate in 1984. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Prolonged incubation period of AIDS in intravenous drug abusers: epidemiological evidence in prison inmates.

J Infect Dis. 1984 Aug;150(2):263-6. Unique Identifier : AIDSLINE MED/84290855
Hanrahan JP; Wormser GP; Reilly AA; Maguire BH; Gavis G; Morse DL

Abstract: Fourteen heterosexual inmates who developed acquired immunodeficiency syndrome (AIDS) while incarcerated in New York state prisons were studied. All 14 had regularly used illicit drugs intravenously in New York City prior to imprisonment. Leukocyte counts on admission to the state prison system--when all of these inmates were well--were depressed by one-third when compared with those in matched intravenous drug-using inmates used as controls (mean leukocyte counts, 4,430 vs. 6,320 cells/mm3, respectively; P less than .005); twelve (86%) of the 14 inmates who developed AIDS had counts of less than 5,000 cells/mm3, compared with only six (14%) of the 42 controls (P less than .00001). The 14 inmates developed AIDS symptoms a mean of 22.6 +/- 9.6 months after imprisonment. We conclude that leukopenia is frequently to be found in presymptomatic AIDS infection and that the minimum mean incubation period of AIDS in intravenous-drug abusers is quite prolonged.
Keywords: Acquired Immunodeficiency Syndrome/BLOOD/*ETIOLOGY/ PHYSIOPATHOLOGY Adult Female Human Injections, Intravenous Leukocyte Count Male Pneumonia, Pneumocystis carinii/COMPLICATIONS *Prisoners Risk Substance Abuse/*COMPLICATIONS Time Factors JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/blood/KWDetiology/physiopathologyadultfemalehumaninjections,intravenousleukocytecountmalepneumonia,pneumocystiscarinii/complicationsKWDprisonersrisksubstanceabuse/KWDcomplicationstimefactorsjournalarticle
841230
M84C0067

Copyright © 1984 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1984. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1984. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .